Tag:
Paladin
Latest Headlines
Latest Headlines
Paladin, Valeant raise stakes in bidding for Afexa
Canada's Afexa Life Sciences has sparked a bidding war. This morning, Paladin Laboratories topped Valeant Pharmaceuticals' 71-cents-a-share bid with an 81-cent offer, but Valeant turned around and
Paladin CEO in hospital after cycling accident
Paladin Labs CEO Jonathan Ross Goodman has been hospitalized after a cycling accident, spooking investors. The company is in the middle of two takeover bids, one involving Afexa Life Sciences and the
Paladin mounts hostile bid for Afexa
Paladin Labs is offering a modest premium in a hostile bid to take over Afexa Life Sciences, which makes the flu drug COLD-FX. In a deal that values the company at $56.7 million, Paladin has bid 55
Paladin acquires early-stage biotech, vax platform
Paladin Labs has completed its acquisition of ViRexx Medical Corp for $1.25 million. Former ViRexx shareholders could receive up to $2.5 million if certain conditions are met within the next week,
